Skip to Content

Regenerx Biopharmaceuticals Inc RGRX

Morningstar Rating
$0.00 −0.05 (97.32%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

RGRX is trading within a range we consider fairly valued.
Price
$0.00
Fair Value
$8.13
Uncertainty
Extreme
1-Star Price
$2.74
5-Star Price
$2.78
Economic Moat
Chtq
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RGRX is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.05
Day Range
$0.000.00
52-Week Range
$0.008.80
Bid/Ask
/
Market Cap
$2,095.75
Volume/Avg
115 / 883

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
3

Valuation

Metric
RGRX
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
RGRX

Financial Strength

Metric
RGRX
Quick Ratio
0.06
Current Ratio
0.07
Interest Coverage
−4.19
Quick Ratio
RGRX

Profitability

Metric
RGRX
Return on Assets (Normalized)
−206.96%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
RGRX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRGpckblzwltKvmpv$557.8 Bil
VRTX
Vertex Pharmaceuticals IncDdjvbrvpQtdthg$104.6 Bil
REGN
Regeneron Pharmaceuticals IncRndykczwHcgknsz$98.8 Bil
MRNA
Moderna IncMphttwngmHknjc$38.8 Bil
ARGX
argenx SE ADRMkqpshswXyg$21.4 Bil
BNTX
BioNTech SE ADRDyrffgkRcwmd$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncBbnbknjyCbgvrg$18.4 Bil
BMRN
Biomarin Pharmaceutical IncKbrqjplcYgprzf$17.5 Bil
RPRX
Royalty Pharma PLC Class AYhbfkkxznQcpxxq$12.4 Bil
INCY
Incyte CorpRqdtdgvvzGnchhnd$11.9 Bil

Sponsor Center